

ZIOPHARM ONCOLOGY INC

Form 8-K

February 12, 2013

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **February 12, 2013**

ZIOPHARM Oncology, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction

of Incorporation)

001-33038

(Commission File Number)

84-1475672

(IRS Employer

Identification No.)

1180 Avenue of the Americas

20th Floor

New York, NY

(Address of Principal Executive Offices) (Zip Code)

10036

(646) 214-0700

(Registrant's telephone number, including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Item 8.01 Other Events

ZIOPHARM Oncology, Inc., or the Company, announced today that the Phase 3 trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma(PICASSO 3) has reached its target number of progression-free survival (PFS) events, and that top line data from PICASSO 3 will be announced by the Company during the last week of March 2013.

A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

- (d) Exhibits

Exhibit No. Description

99.1 Press release of the Company dated February 12, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZIOPHARM Oncology, Inc.

By: /s/ Jason A. Amello

Date: February 12, 2013

Name: Jason A. Amello

Title: Executive Vice President and Chief Financial Officer

INDEX OF EXHIBITS

Exhibit No. Description

99.1 Press release of the Company dated February 12, 2013

